* SUCCESSFUL PREDICTION OF CANCER RESPONSE TO LIPLACIS® IN BREAST CANCER AND OTHER TUMORS BY OV'S DRP™ - STRONG SUPPORT FOR RANDOMIZED PHASE 2

* ‍DATA FROM ONGOING LIPLACIS PHASE 1/2 STUDY SHOWS TUMOR RESPONSE TO LIPLACIS CAN BE PREDICTED BY ONCOLOGY VENTURES DRP INDEPENDENT OF TUMOR TYPE AND INCLUDING BREAST CANCER​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)